Legal & General Group PLC Keros Therapeutics, Inc. Transaction History

Legal & General Group PLC

$431 Billion
Q3 2025

A detailed history of Legal & General Group PLC transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 3,117 shares of KROS stock, worth $53,799. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,117

Previous 3,117 -0.0%

Holding current value

$53,799

Previous $41,000 19.51%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	SELL	$9.55 - $15.11 $27,093 - $42,867	-2,837 Reduced 47.65%	3,117 $41,000
Q1 2025 May 15, 2025	SELL	$10.15 - $16.1 $264,062 - $418,857	-26,016 Reduced 81.38%	5,954 $60,000
Q4 2024 Feb 13, 2025	BUY	$15.64 - $70.0 $2,236 - $10,010	143 Added 0.45%	31,970 $506,000
Q3 2024 Feb 28, 2025	SELL	$41.68 - $58.07 $118,996 - $165,789	-2,855 Reduced 8.93%	29,115 $1.69 Million
Q2 2024 May 29, 2025	BUY	$44.58 - $66.89 $163,162 - $244,817	3,660 Added 14.38%	29,115 $1.33 Million

Q2 2024 Aug 14, 2024	BUY	$44.58 - $66.89 $284,063 - $426,223	6,372 Added 25.03%	31,827 $1.45 Million
Q1 2024 May 29, 2025	BUY	$41.26 - $70.48 $804,611 - $1.37 Million	19,501 Added 327.53%	25,455 $1.69 Million
Q1 2024 Jul 01, 2024	BUY	$41.26 - $70.48 $35,978 - $61,458	872 Added 3.55%	25,455 $1.69 Million
Q1 2024 May 14, 2024	BUY	$41.26 - $70.48 $235,470 - $402,229	5,707 Added 30.23%	24,583 $1.63 Million
Q4 2023 May 29, 2025	BUY	$27.12 - $41.05 $350,444 - $530,448	12,922 Added 217.03%	18,876 $750,000
Q4 2023 Feb 15, 2024	SELL	$27.12 - $41.05 $1,356 - $2,052	-50 Reduced 0.26%	18,876 $750,000
Q3 2023 Nov 14, 2023	BUY	$31.57 - $43.02 $26,203 - $35,706	830 Added 4.59%	18,926 $603,000
Q2 2023 Aug 14, 2023	BUY	$37.26 - $51.01 $318,535 - $436,084	8,549 Added 89.55%	18,096 $727,000
Q1 2023 May 15, 2023	BUY	$41.44 - $59.32 $60,668 - $86,844	1,464 Added 18.11%	9,547 $407,000
Q4 2022 Feb 14, 2023	BUY	$39.45 - $51.77 $17,436 - $22,882	442 Added 5.78%	8,083 $388,000
Q3 2022 Nov 14, 2022	BUY	$27.8 - $40.12 $20,905 - $30,170	752 Added 10.92%	7,641 $287,000
Q2 2022 Aug 22, 2022	BUY	$26.03 - $67.04 $911 - $2,346	35 Added 0.51%	6,889 $190,000
Q1 2022 May 16, 2022	BUY	$42.12 - $59.36 $29,652 - $41,789	704 Added 11.45%	6,854 $373,000
Q4 2021 Feb 14, 2022	BUY	$36.95 - $62.89 $221 - $377	6 Added 0.1%	6,150 $360,000
Q3 2021 Nov 15, 2021	BUY	$29.27 - $43.71 $73,731 - $110,105	2,519 Added 69.49%	6,144 $243,000
Q2 2021 Aug 12, 2021	BUY	$42.4 - $70.11 $8,861 - $14,652	209 Added 6.12%	3,625 $154,000
Q1 2021 May 17, 2021	SELL	$54.0 - $75.28 $3,456 - $4,817	-64 Reduced 1.84%	3,416 $211,000
Q4 2020 Feb 12, 2021	BUY	$36.0 - $82.74 $95,112 - $218,599	2,642 Added 315.27%	3,480 $245,000
Q3 2020 Nov 13, 2020	SELL	$27.04 - $62.21 $7,841 - $18,040	-290 Reduced 25.71%	838 $32,000
Q2 2020 Aug 14, 2020	BUY	$20.08 - $40.39 $22,650 - $45,559	1,128 New	1,128 $42,000

Others Institutions Holding KROS

# of Institutions

169

Shares Held

35.4M

Call Options Held

574K

Put Options Held

325K

View Full List

About Keros Therapeutics, Inc.

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $445M
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

More about KROS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Keros Therapeutics, Inc. Transaction History